selection evaluation clinically relevant aav variants xenograft liver model 
recombinant adeno-associated viral raav vectors shown early promise clinical trials- therapeutic transgene cassette can packaged different aav capsid pseudotypes unique transduction profile present raav capsid serotype selection specific clinical trial based effectiveness animal models however preclinical animal studies always predictive human outcome- attempt understanding discrepancies used chimaeric human-murine liver model compare directly relative efficiency raav transduction human versus mouse hepatocytes vivo predicted preclinical clinical studies raav2 vectors functionally transduced mouse human hepatocytes equivalent relatively low levels however raav8 vectors effective many animal models transduced human hepatocytes rather poorly-approximately times less efficiently mouse hepatocytes light limitations raav vectors currently used clinical studies used murine chimaeric liver model perform serial selection using human-specific replication-competent viral library composed dna-shuffled aav capsids one chimaeric capsid composed five different parental aav capsids found transduce human primary hepatocytes high efficiency vitro vivo provided species-selected transduction primary liver cultured cells hepatocellular carcinoma xenograft model vector ideal clinical candidate reagent gene modification human xenotransplants mouse models human diseases importantly results suggest humanized murine models may represent precise approach selecting evaluating clinically relevant raav serotypes gene therapeutic applications 
